Breaking: Samsung Bioepis and Celltrion Forge Ahead in Psoriasis Biosimilar Market
Google News Alert: Recent Developments in Psoriasis Treatment Could Transform Global Healthcare
Psoriasis, a chronic inflammatory skin disease affecting over 1.5 million people in Korea, is on the radar of global pharmaceutical and bio industries. Despite the significant prevalence, less than 15% of these patients receive proper treatment, a significant concern as psoriasis is more than just a surface skin issue; it increases the risk of systemic complications like hypertension, diabetes, and hyperlipidemia.
Understanding Psoriasis and Its Impact
Psoriasis is caused by the activation of T cells, which in turn stimulates keratinous cells to proliferate rapidly, resulting in the abnormal accumulation of keratin. The market for psoriasis treatment is expected to experience a robust growth of about 10% annually, rising from $27.2 billion to an estimated $57.7 billion by 2032, globally.
Innovative Biosimilars Ensuring Accessibility
Leading the charge in this lucrative market are the biosimilar drug developers, Samsung Bioepis and Celltrion. Samsung Bioepis has developed ‘Fizzi Bar,’ a biosimilar of Janssen’s ‘Stelara,’ targeting autoimmune diseases including plaque psoriasis, psoriasis arthritis, and Crohn’s disease. This biosimilar, already sold in the United States, is a testament to advancements in biopharmaceuticals.
Simultaneously, Celltrion has introduced ‘Stecima,’ another biosimilar targeting psoriasis, approved and sold in the United States. These developments come in the aftermath of BMS’s oral drug ‘Sotina,’ approved by the FDA, which targets the Tyk2 signal transmission pathway in inflammatory responses, a promising approach beyond the traditional neutralization of inflammatory substances.
The Long-Term Implications
Experts underline the need for a long-term approach in treating psoriasis due to its recurring nature. The integration of biosimilars offers patients sustainable relief, potentially transforming access and affordability within the healthcare sector.
With over 1.5 million patients in Korea alone, the attention on effective treatment is pivotal. By advancing biosimilars, Samsung Bioepis and Celltrion are not only addressing a crucial healthcare need but also contributing to a burgeoning market with extensive growth potential.
Stay tuned for more updates on the latest breakthroughs in the biopharmaceutical industry and how they’re reshaping healthcare everywhere.
